bio sketch column
Iván Cornella-Taracido Ph.D. is a Director of Chemical Biology at Merck & Co. Pharmaceuticals in Boston, MA. He is the co-chair of the Phenotypic Screening Initiative at Merck Research Laboratories and responsible for creating a framework to leverage Chemical Biology towards building novel early discovery competencies with a particular emphasis in chemo-proteomics, chemo-genomics and chemical probe development for target identification and validation. In his prior career at Novartis, Sanofi and AstraZeneca, Iván has created and lead Chemical Biology teams responsible for advancing phenotypic and signaling pathway screening projects towards mechanism of action elucidation and validation, working across multiple disease areas and therapeutic indications, such as oncology, infection, fibrosis and immunology. Using chemogenetics and chemoproteomics techniques and integrating medicinal and synthetic chemistry with molecular biology, pharmacology and informatics in multidisciplinary team efforts, he has contributed to the elucidation of the mechanism of action of natural and synthetic bioactive small molecules. Prior to moving to pharma, Iván was a US National Cancer Institute Initiative for Chemical Genetics Postdoctoral Research Fellow at the Institute of Chemistry & Cell Biology of Harvard Medical School and NIH Postdoctoral Research Fellow at Boston College. He received his PhD from the Universidade da Coruña (UdC), Spain.